Key Technology

R & D

Key Technology

The development of a new peptide drug that suppresses protein-protein interaction

Peptide therapeutic agents that block signal transduction mediated by protein-protein interaction, fused with fuctional penetrating peptide

GSP Libraries target diseases

Starting with drugs for autoimmune disease, a wide variety of expansion to cancer, neuronal diseases, fibrosis and PROTAC(Proteolysis Targeting Chimeras) is feasible.

Platform Technology

Toll-like Receptor(TLR)

 

A key factor in innate and adaptive immunity

Discovered in 2011 by Bruce A, Beautler et al (Nobel Prize awarded)

Disease induction via abnormal (autoimmune) and excessive (inflammatory) response

Is known to take part in Lupus, Rheumatoid Arthritis, Psoriasis, etc.

Our Pipeline – GSP Series

 

Suppressing Pan-TLR signal transduction by blocking intracellular protein-protein interaction

comprised of Cell-Penetrating Peptide and TIRAP-derived amino acid sequences (TIRAP:Toll/Interleukin-1 Receptor domain-containing Adaptor Protein)

TLR Decoy Peptide

Target Specificity

Safe

Predictable Metabolism